~~<i id='4F00219245'><strike id='4F00219245'><tt id='4F00219245'><pre id='4F00219245'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

author：focus 2025-10-01 02:12:08 - browse：6

Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： How the first Native Hawaiian psychiatrist helped diversify medicine

focus

hotspot

focus

explore

focus

leisure time

Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb

WSS

Meadows told special counsel he could not recall Trump ever declassifying Mar

In key trial, Verve's treatment lowers cholesterol levels in patients

How to make over

A daunting task: navigating dual Medicare, Medicaid eligibility

Listen: Vivek Ramaswamy's star turn & leaky drug data

World's first CRISPR

hotspot

hotspot

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Virginia high school admissions case could be legal follow

World's first CRISPR

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Gain of function research would be limited under House proposal

DIEP, the 'gold standard' of breast reconstruction, is under threat

World's first CRISPR

Heart attack and stroke risk calculators need revising

Trans patients at the end of life deserve respect and dignity

hotspot

FDA greenlights medical device to combat bladder issues

Hospital at home shows how to bring innovation to health care

World's first CRISPR

Former Pear Therapeutics executives start new VC firm

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Former Pear Therapeutics executives start new VC firm

focus

explore

focus

leisure time